TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report)’s share price passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $0.87 and traded as high as $0.9399. TriSalus Life Sciences shares last traded at $0.9420, with a volume of 1,810 shares changing hands.
TriSalus Life Sciences Price Performance
The firm’s 50-day moving average is $0.87 and its 200 day moving average is $0.97.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in TriSalus Life Sciences stock. State Street Corp bought a new stake in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 610,963 shares of the company’s stock, valued at approximately $2,780,000.
About TriSalus Life Sciences
TriSalus Life Sciences is a medical technology and therapeutics company focused on improving treatment delivery for patients with solid tumors, particularly tumors in the liver and pancreas. Its approach combines proprietary drug-delivery technology with the development of immunotherapies.
The company’s TriNav® infusion system is designed to deliver therapies into tumors using its Pressure-Enabled Drug Delivery (PEDD) approach. TriSalus is also developing investigational therapies intended to work alongside its delivery platform; these therapies are not established treatments.
TriSalus became a publicly traded company in 2023 through a business combination with MedTech Acquisition Corporation.
Further Reading
- Five stocks we like better than TriSalus Life Sciences
- GE Aerospace Has a $170 Billion Backlog, But Is the Stock Worth the Premium?
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
